Abstract

This twelvemonth, in 2018, we mark 100 years since the 1918 influenza pandemic. In the last 100 years, nosotros accept expanded our knowledge of public health and increased our power to detect and prevent influenza; however, we still face challenges resulting from these continually evolving viruses. Today, it is clear that influenza viruses take multiple animal reservoirs (domestic and wild), making infection prevention in humans especially hard to achieve. With this study, we summarize new knowledge regarding influenza A, B, C and D viruses and their command. We also introduce how a multi-disciplinary One Health approach is necessary to mitigate these threats.

INTRODUCTION

In 2018, we mark the centennial of the 1918 influenza pandemic; an event that caused an estimated twenty–fifty million deaths worldwide [i]. The severity of the 1918 pandemic was a consequence of several of import factors including a lack of pre-existing immunity to this newly emerged virus, as well as overcrowding, poor sanitation and the lack of antibiotics. However, despite the production of annually designed vaccines and the many improvements in public health surveillance and infrastructure, each yr in the United states alone, seasonal influenza A and B viruses continue to evolve and have the lives of 3000–48 000 people [ii]. It is now likewise articulate that other related viruses (influenza C and D viruses) may also cause at to the lowest degree subclinical infections in humans. In curt, the ecology of flu viruses is recognized today as i of the most complex and hard to mitigate public health issues.

A key component to this complexity is the observation that influenza A, B, C and D viruses may have numerous animate being species reservoirs (domestic and wild), making their infection prevention in humans especially difficult to achieve. It besides seems articulate in at least recent years that the near important influenza A virus threats to humans are often amplified in domestic animals. Modern agricultural practices, such as the worldwide shift towards raising pork and chickens in confined brute feeding operations (CAFOs) may be amplifying these public health threats [3]. It is also very relevant that human being-reservoired influenza viruses are being introduced into swine CAFOs and sometimes causing large and of import clinical disease outbreaks amidst the pigs [4, 5]. Some might contend that the solution is to heighten pigs in less animal-dumbo farms just this position is simply not realistic. It is through modern agricultural techniques, that include CAFOs, that nearly nations are seeking to produce increase meat production to the increasing demands of rapidly growing human being populations.

Hence, we need to observe new means to engage professionals in human health, creature wellness, environmental wellness and agronomical businesses to piece of work together to report the environmental of influenza viruses, and to jointly develop and test interventions to reduce their risk to humans and animals. This is the premise backside the One Health approach. Although the interconnections of humans and animals have long been recognized [half dozen], One Health was first officially recognized by the American Veterinary Medical Clan in 2007. 1 Health calls for deliberate and focused collaborations between experts in the animal, human and ecology wellness fields. A holistic and versatile One Wellness arroyo is now recognized equally imperative in fostering the effective communication and deportment needed to respond to flu virus threats. Over the last 100 years, this approach has evolved from isolated disciplines working together only in times of pandemic to the continued push button today for collaboration from public health workers, medical professionals, veterinarians and many others. This shift has changed the way influenza, and pandemic influenza in item, are approached with an increase in communication, partnership and outreach when tackling these problems.

Evolutionary medicine is a subject that uses evolutionary theory to understand health and disease [7]. The key focus of this framework is that selection acts on fitness and that evolution and adaption alone do not cause disease. I Health and evolutionary medicine are interconnected in that both crave an interdisciplinary approach to complex problem solving. Ofttimes both disciplines work at the intersection of irresolute environments, animal and homo habitats. In item, with the instance of influenza, the continued evolution and accommodation to new and diverse host species, every bit shown in Effigy 1, presents a unique trouble that requires the use of both disciplines.

Figure i.

Graphical summary of the reports of human and animal infections with the various influenza viruses (Genera influenza virus A, B, C, & D). It is interesting to note that humans and pigs are thought to be susceptible to all four influenza genera. Among the animals with documented influenza infections, many are domestic animals. In particular, poultry and pigs serve as important amplifying reservoirs for influenza A virus infections in man

Graphical summary of the reports of human and animal infections with the various influenza viruses (Genera influenza virus A, B, C, & D). It is interesting to notation that humans and pigs are thought to be susceptible to all four influenza genera. Among the animals with documented influenza infections, many are domestic animals. In item, poultry and pigs serve as of import amplifying reservoirs for influenza A virus infections in man

Effigy 1.

Graphical summary of the reports of human and animal infections with the various influenza viruses (Genera influenza virus A, B, C, & D). It is interesting to note that humans and pigs are thought to be susceptible to all four influenza genera. Among the animals with documented influenza infections, many are domestic animals. In particular, poultry and pigs serve as important amplifying reservoirs for influenza A virus infections in man

Graphical summary of the reports of human and animal infections with the various influenza viruses (Genera influenza virus A, B, C, & D). It is interesting to note that humans and pigs are thought to exist susceptible to all four influenza genera. Among the animals with documented flu infections, many are domestic animals. In item, poultry and pigs serve equally important amplifying reservoirs for influenza A virus infections in human

With this report, we will outline newly described flu virus types and subtypes and novel developments in influenza virus detection and control. We also introduce how an interdisciplinary One Health arroyo seems the best way forward to mitigating these threats.

INFLUENZA A VIRUS

Flu A virus (IAV) [8] is highly infectious and can be transmitted to humans via directly contact with secretions, aerosolized respiratory aerosol and indirect contact with fomites. Known for its high morbidity and mortality rates, IAV is the crusade of both seasonal and celebrated influenza pandemics, including the severe 1918 H1N1 pandemic, the 1957 H2N2 'Asian Flu' pandemic, the 1968 H3N2 pandemic, and nearly recently the 2009 novel H1N1 virus pandemic, the latter of which likely emerged from domestic pigs resulted in between 151 700 and 575 400 man deaths worldwide [nine].

More recently, influenza activity during the 2017–18 flu season has been the highest nevertheless since the 2009 pandemic, with a cumulative incidence rate of 59.9 influenza-hospitalizations per 100 000 people in the USA [10]. IAVs constituted 84% of the more 51 000 specimens tested in public health laboratories beyond the United states of america and Puerto Rico between October of 2017 and February of 2018 [10]. Of the IAV subtypes, 89.ix% were IAV H3N2 viruses and ten.1% were IAV H1N1 viruses. More than than 71% of the 63 influenza-associated pediatric deaths this 2017–18 influenza season were associated with IAV infections, a slightly higher proportion than the overall proportion (65%) of pediatric deaths owing to IAV infection between 2010 and 2016 in the USA [10].

Growing numbers of avian-origin IAVs, which include 16 of the 18 hemagglutinin glycoprotein subtypes and 9 of the 11 neuraminidase (NA) subtypes, are increasingly establish to infect humans. Due to increases in the number of human infections with avian-origin H7N9 IAV in Cathay in 2017, a study of 40 example-patient clusters across 5 recent epidemics from 2013 to 2017 sought to determine if human-to-human manual of H7N9 has increased in the past five years. While the written report establish no change in the human-to-man transmission of H7N9 over time, among the 40 clusters, 35% were classified as probable and 65% as possible human being-to-homo transmission [xi]. Sustained human-to-human transmission, however, has not been seen between epidemics, suggesting that non-human animals are important for maintenance of this virus. Humans infected with H7N9 typically present with severe symptoms and the mortality charge per unit is ∼40%.

Environments that facilitate IAV include birds [12], pigs [13], horses [14], dogs [15] and most recently bats [16]. In particular, aquatic birds are considered the primordial reservoir of all flu viruses for avian and mammalian species. Evidence continues to back up the assertion that environments that facilitate the interaction of human and avian species, such as the live poultry markets, oftentimes increment transmission hazard to humans [12]. During the 2013 and 2014 IAV (H7N9) outbreak in China, for example, the majority of patients with laboratory-confirmed cases of IAV (H7N9) reported recent exposure to live poultry markets [17]. A type of avian IAV (H7N4) was detected in a man patient, with a reported history of contact with live poultry, for the first fourth dimension in February of 2018, prompting government to exist on warning for the pandemic potential of the virus [18]. Additionally, multiple studies take provided prove of bidirectional transmission of IAV at the interface of human and pig populations, particularly at agricultural fairs [13, 19]. Asymptomatic hog entrants in these public showroom spaces are suspected viable facilitators for IAVs to jump between species [13]. Compared with other influenza types, the zoonotic transmission of IAV has been oft documented and findings on the trans-species paths of infection indicate the expanding potential for new strains of IAV to sally at the human and beast interface. There will probable exist a continued need for effective control and prevention of emerging zoonotic IAV. Every bit such, surveillance efforts for IAV would benefit from a One Wellness approach that would employ surveillance at the human–fauna interface where novel subtypes are about probable to threaten the human being population.

A select few antivirals accept been approved and demonstrated effective to reduce symptoms of IAV and concurrently reduce transmission. These are summarized in Table one. Oseltamivir, peramivir and zanamivir are iii NA inhibitor antiviral interventions. Two M2 ion aqueduct inhibitors (amantadine and rimatadine) have also been canonical.

Table i.

Characteristics of influenza viruses

Virus blazon Yr of virus discovery Number of factor segments Bachelor antiviral therapy Seasonal vaccine routinely bachelor
Influenza A 1931 8 Oseltamivir, peramivir, zanamivir, amantadine, rimatadine Aye
Influenza B 1940 8 Oseltamivir, zanamivir Yes
Flu C 1974 7 No effective antiviral treatment available No
Flu D 2011 7 No antiviral handling bachelor No
Virus type Yr of virus discovery Number of gene segments Available antiviral therapy Seasonal vaccine routinely bachelor
Influenza A 1931 eight Oseltamivir, peramivir, zanamivir, amantadine, rimatadine Yes
Influenza B 1940 8 Oseltamivir, zanamivir Yes
Influenza C 1974 7 No effective antiviral handling bachelor No
Influenza D 2011 7 No antiviral treatment available No

Table 1.

Characteristics of influenza viruses

Virus type Yr of virus discovery Number of gene segments Available antiviral therapy Seasonal vaccine routinely bachelor
Flu A 1931 8 Oseltamivir, peramivir, zanamivir, amantadine, rimatadine Aye
Influenza B 1940 8 Oseltamivir, zanamivir Aye
Influenza C 1974 7 No effective antiviral handling available No
Influenza D 2011 7 No antiviral treatment available No
Virus type Year of virus discovery Number of gene segments Available antiviral therapy Seasonal vaccine routinely available
Influenza A 1931 8 Oseltamivir, peramivir, zanamivir, amantadine, rimatadine Yes
Influenza B 1940 eight Oseltamivir, zanamivir Yes
Influenza C 1974 7 No effective antiviral treatment available No
Influenza D 2011 seven No antiviral treatment available No

Evolutionary perspectives are important in considering treatment options. For case, near IAV strains have developed resistance to the M2 ion channel blockers; thus, amantadine drugs are not currently being recommended for preventing or treating influenza [20]. While NA inhibitor medications are the current recommended interventions, concerns are growing over the emergence of oseltamivir-resistant strains. Since October 2017, the CDC found 1.ane% of 376 H1N1 IAV strains are resistant to both oseltamivir and peramivir; all the same, all 903 H3N2 viruses tested were susceptible to both oseltamivir and zanamivir [x]. New monoclonal therapies are under development which may increase therapeutic options for patients with severe IAV disease [21].

For salubrious adults, annual trivalent or quadrivalent flu vaccines accept been the major prophylactic prevention mechanism for several decades. In order to inform the selection of the viral composition of season vaccines, robust active surveillance and epidemiological and evolutionary modeling is required to predict the upcoming seasonal strains that will circulate in the Northern and Southern hemispheres. Mismatches can occur, due in part to frequent minor changes in virus glycoproteins occurs between the fourth dimension when the strains are selected and the time the vaccine is produced, reducing the effectiveness of the vaccine as was the example during this 2017–xviii influenza flavour. Electric current vaccine effectiveness (VE) estimates of the 2017–18 vaccine are estimated at 36% overall with 25% VE specifically against H3N2-related illness and 67% VE confronting H1N1 viruses [22]. When because vaccine options and effectiveness, there are several important scientific and policy considerations related to availability, access and prevention of future disease. From a One Health perspective, other virus hosts and reservoirs of IAV should be considered in the development of future vaccines likewise equally the surveillance of resistance in the surroundings.

INFLUENZA B VIRUS

In the bound of 1940, flu B virus (IBV) was offset identified from a child during an acute respiratory epidemic in the The states [23]. Since then IBV strains have been recognized to cause considerable seasonal morbidity and mortality with B/Victoria/2/87-like (Victoria lineage) and B/Yamagata/sixteen/88-like (Yamagata lineage) strains being the virtually prevalent [24]. During influenza seasons, IBV, forth with IAV (H1N1) or H3N2 co-circulate and become the nearly prevalent strains every two–fourteen years [25]. Compared with IAV, IBV has less antigenic variation and fewer subtypes [26]. Despite being considered less of a public health threat than IAV, IBV has been reported with prevalence of up to 82.4% among individuals reporting influenza-similar illness (ILI) [27] and symptoms such as encephalitis, myositis, even death have been previously reported [28].

IBV is mainly associated with human being infection [29]; however, other creature reservoirs have been proposed, suggesting that a One Health perspective is besides important for this influenza virus. Pigs are susceptible to IBV and may serve as a natural reservoir [30]. Additionally, antibodies against IBV have been isolated from horses and pigs in Japan [31] and from dogs in Taiwan [32]. In 1999, influenza B was isolated from a harbor seal with a respiratory disease that was associated with a large seal die-off in the Netherlands. Phylogenetic analyses of viruses obtained from seal serum indicated that the IBV was of homo origin [29]. Thus far, no novel seal-reservoired IBV strains have been detected and no evidence of IBV seal to man manual has been reported.

At present, there are 2 canonical antiviral drugs (NA inhibitors oseltamivir and zanamivir) for IBV infection [33]. Oseltamivir is the most widely administered for the prophylaxis and treatment of IBV infection in patients older than i year [34]. Zanamivir is administered to patients older than vii years by inhalation and functions directly in the respiratory tract [34]. Several studies show that oseltamivir is less effective in treating IBV compared with the treatment of IAV [35], zanamivir was equally constructive for IAV and IBV infections and more effective than oseltamivir for the treatment of IBV [35]. However, evolutionarily new NA inhibitor (NAI)-resistant IBV viruses pose a public wellness business organization as they are not susceptible to oseltamivir or zanamivir [36]. IBV variants, including R152K, D198N, G109E and G402S, R152K have been identified equally NAI-resistant [36]. In addition to antiviral therapies, currently a quadrivalent influenza vaccine, including ii influenza A subtypes (H1N1 and H3N2) and ii influenza B lineages (Victoria and Yamagata) are available [37].

As IBVs go along to pose a significant risk to the public, especially for children and the immunocompromised, better therapies for IBV are greatly needed. From an evolutionary perspective it is of import to choose vaccines and therapies that are relevant to the new and evolving viruses and further research should be targeted to limit further development of resistance or virulence in IBV variants. Similarly from a One Wellness perspective, it is important to choose vaccines that incorporate information from new and novel strains that emerge from host species.

INFLUENZA C VIRUS

First identified in humans in 1974, the near common reservoir for flu C virus (ICV) is humans, with upwardly to 80% of individuals acquiring antibodies to ICV by the age of 7–ten years [38]. Although ICV infections are typically reported at extremely low frequency, they are reported consistently. A study of Eastern Indian patients with acute respiratory illness reported that 0.xviii% were ICV-positive from January 2011 to December 2012 [39]. In Scotland, ICV was present in 0.2% of the 3300 human respiratory samples amidst patients <2 years or >45 years old during the summer and winter between 2006 and 2008 [40]. ICV outbreaks were also reported in Singapore, Japan and French republic betwixt 2004 and 2007 [41]. Additionally, ICV epidemics have been reported in Australia approximately every 2 years during the years of 2010, 2012 and 2014 [42]. One proposed reason for this pattern involves evolutionary modify, driven by a high frequency of reassortment in ICV.

ICV has been known to naturally infect domestic pigs [43] and feral dogs [44]. When feral dogs were nasally infected with homo ICV, they adult clinical symptoms while shedding the virus for more than 10 days, suggesting that dogs may serve as natural reservoirs for human ICV [44]. In addition, in a 2017 ICV antibody study, dromedary camels in Kenya were suspected to serve every bit a newly recognized host for ICV equally they were found to harbor ICV antibodies [45]. This recent discovery suggests that ICV, such as IAV and IBV, may have a wider host range than previously thought. Thus, a One Health approach to surveillance amongst animals and amidst environments is needed for ICV, specially where extended interactions between animals and humans may favor spillover of the virus.

As the symptoms associated with ICV are less astringent in comparison with other forms of influenza and respiratory infection [46], less attending has been drawn to developing antivirals and vaccines against ICV. Hence there are no constructive antiviral treatments or vaccines available for ICV [42]; however, in the development of future therapies for ICV, it will exist important to take a I Health approach to evaluate the animal reservoirs for this virus and their potential impact on the spread of the virus in humans.

Influenza D VIRUS

In 2011, a viral isolate with ∼50% amino acid homology to human ICV was collected from a pig exhibiting ILI in Oklahoma [47]. Although initially believed to be a subtype of ICV, this virus has now been recognized as a new genus in the Orthomyxoviridae family: influenza D virus (IDV). Antibodies of IDV have been detected in pigs, cattle, goats and sheep. In animals, the highest prevalence of IDV has been detected in cattle with symptoms of bovine respiratory disease, particularly in calves (half-dozen–viii months) due to their underdeveloped immune system [48]. Serological prove indicates IDV has been present in US cattle populations since as early as 2004 [43]. A cross-exclusive serological report of cattle-exposed adults in Florida constitute a high prevalence (97%) of neutralizing antibodies compared to non-exposed controls (18%) suggesting occupational exposure chance [49]. Similarly, a study conducted on cattle in Mississippi showed 94% seroprevalence in neonatal beef cattle in addition to IDV transmission in comingled cattle herds [50]. During a swine respiratory disease outbreak in Northern Italy in 2015, the IDV genome was detected and isolated in both pigs and cattle herds [51]. The IDV genome isolated from the pigs was closely related to the viral genome isolated in the Us in 2011. Additionally, the archived serum samples from 2011 had lower IDV antibody titers when compared with the serum samples collected in 2015, suggesting that the incidence of IDV infections in pigs may have increased over time, and therefore, IDV may pose a public health threat to the community.

Relatively little is known about the potential zoonotic transmission of IDV to humans [47], and to appointment the signs and symptoms of acute IDV in humans have non been described. With the increased potential of IDV transmission in and between animal reservoirs, and the high presence of neutralizing antibodies in cattle exposed workers, there is a need to determine if IDV is zoonotic through One Health oriented surveillance. Currently there is no recommended therapy or vaccine bachelor for IDV.

CONCLUSION AND Future DIRECTIONS

Since the 1918 influenza pandemic, there have been many changes to public health infrastructure as well every bit new developments in vaccine technologies. Despite this, influenza viruses exhibit remarkable evolutionary modify and accommodation to new creature hosts. The One Health approach has been proposed every bit a fashion to work beyond disciplines to incorporate human, animal and ecology wellness in guild to solve complex issues, such as infectious disease outbreaks. Novel One Health strategies for future surveillance may include bioaerosol surveillance at the human being–beast interface. These alternative strategies are advantageous due to low cost, less invasive sampling methods that are acceptable to industry [52–56].

Today, novel enquiry on influenza viruses is conducted non only by medical doctors and vaccines scientists, but also veterinarians and the agronomical manufacture seeking to reduce influenza virus morbidity in animal hosts. Additionally, during the 2009 H1N1 pandemic the global community was informed and a vaccine was prepared in record response fourth dimension as a result of international, multidisciplinary collaboration.

In the future, it will be increasingly important for multiple disciplines to collaborate in studying influenza viruses in an effort to mitigate flu virus outbreaks in both humans and animals. As these viruses continue to evolve, particularly in relation to virulence, resistance and ecology, there is a need for rigorous collaboration using the 1 Health approach to prevent not only future outbreaks but also to track the spread of infectious disease.

Funding

This study was supported in part by NIH/NIAID grant R01AI108993-01A1 (Grayness PI).

Disharmonize of interest: None declared.

REFERENCES

1

Johnson

NP

,

Mueller

J.

Updating the accounts: global mortality of the 1918–1920 "Spanish" influenza pandemic

.

Bull Hist Med

2002

;

76

:

105

–

15

.

ii

Centers for Disease Control and Prevention

.

Estimates of deaths associated with seasonal influenza—U.s.a., 1976–2007

.

MMWR Morb Mortal Wkly Rep

2010

;

59

:

1057

–

62

.

3

Saenz

RA

,

Quinlivan

Thou

,

Elton

D

 et al.

Dynamics of influenza virus infection and pathology

.

J Virol

2010

;

84

:

3974

–

83

.

4

Nelson

MI

,

Tan

Y

,

Ghedin

Eastward

 et al.

Phylogeography of the leap and fall waves of the H1N1/09 pandemic influenza virus in the United states of america

.

J Virol

2011

;

85

:

828

–

34

.

5

Messenger

AM

,

Barnes

AN

,

Grey

GC.

Reverse zoonotic disease transmission (zooanthroponosis): a systematic review of seldom-documented human biological threats to animals

.

PLoS I

2014

;

ix

:

e89055

vi

Gibbs

EP.

The evolution of One Health: a decade of progress and challenges for the future

.

Vet Rec

2014

;

174

:

85

–

91

.

7

Gluckman

PD

,

Low

FM

,

Buklijas

T

 et al.

How evolutionary principles improve the agreement of man health and disease

.

Evol Appl

2011

;

iv

:

249

–

63

.

eight

Debiaggi

1000

,

Canducci

F

,

Sampaolo

M

 et al.

Persistent symptomless human metapneumovirus infection in hematopoietic stalk cell transplant recipients

.

J Infect Dis

2006

;

194

:

474

–

8

.

nine

Saunders-Hastings

PR

,

Krewski

D.

Reviewing the history of pandemic flu: understanding patterns of emergence and transmission

.

Pathogens

2016

;

5

:

66

.

10

Budd

AP

,

Went

DE

,

Blanton

Fifty

 et al.  Update: influenza activity—United States, October 1, 2017–February 3,

2018

.

MMWR Morb Mortal Wkly Rep

67

:

169

–

79

.

11

Zhou

L

,

Chen

E

,

Bao

C

 et al.

Clusters of human infection and homo-to-man transmission of avian flu A(H7N9) Virus, 2013–2017

.

Emerg Infect Dis

2018

;

24

:

397

–

400

.

12

Hill

NJ

,

Runstadler

JA.

A bird'due south eye view of influenza A virus transmission: challenges with characterizing both sides of a co-evolutionary dynamic

.

Integr Comp Biol

2016

;

56

:

304

–

16

.

13

Bowman

AS

,

Nolting

JM

,

Nelson

SW

,

Slemons

RD.

Subclinical influenza virus A infections in pigs exhibited at agronomical fairs, Ohio, U.s., 2009–2011

.

Emerg Infect Dis

2012

;

18

:

1945

–

50

.

14

Xie

T

,

Anderson

BD

,

Daramragchaa

U

 et al.

A review of evidence that equine flu viruses are zoonotic

.

Pathogens

2016

;

v

:

fifty

.

15

Payungporn

S

,

Crawford

PC

,

Kouo

TS

 et al.

Influenza A virus (H3N8) in dogs with respiratory disease, Florida

.

Emerg Infect Dis

2008

;

14

:

902

–

8

.

xvi

Tong

S

,

Li

Y

,

Rivailler

P

 et al.

A singled-out lineage of influenza A virus from bats

.

Proc Natl Acad Sci The states

2012

;

109

:

4269

–

74

.

17

Wu

P

,

Jiang

H

,

Wu

JT

 et al.

Poultry market closures and human being infection with influenza A(H7N9) virus, China, 2013–14

.

Emerg Infect Dis

2014

;

twenty

:

1891

–

4

.

19

Gray

GC

,

Bender

JB

,

Bridges

CB

 et al.

Flu A(H1N1)pdm09 virus amongst healthy show pigs, Us

.

Emerg Infect Dis

2012

;

18

:

1519

–

21

.

20

Moorthy

NSHN

,

Poongavanam

V

,

Pratheepa

V.

Viral M2 ion channel protein: a promising target for anti-influenza drug discovery

.

Mini Rev Med Chem

2014

;

14

:

819

–

thirty

.

21

Tharakaraman

K

,

Subramanian

5

,

Viswanathan

K

 et al.

A broadly neutralizing homo monoclonal antibiotic is constructive against H7N9

.

Proc Natl Acad Sci USA

2015

;

112

:

10890

–

5

.

22

Flannery

B

,

Chung

JR

,

Belongia

EA

 et al.

Interim estimates of 2017–18 seasonal influenza vaccine effectiveness—United States, February 2018

.

MMWR Morb Mortal Wkly Rep

2018

;

67

:

180

–

5

.

23

Francis

T.

Jr,

A new type of virus from epidemic influenza

.

Science

1940

;

92

:

405

–

8

.

24

Rota

PA

,

Wallis

TR

,

Harmon

MW

 et al.

Cocirculation of ii distinct evolutionary lineages of influenza type B virus since 1983

.

Virology

1990

;

175

:

59

–

68

.

25

Glezen

WP.

The changing epidemiology of respiratory syncytial virus and influenza: impetus for new control measures

.

Pediatr Infect Dis J

2004

;

23

:

S202

–

6

.

26

Chen

R

,

Holmes

EC.

The evolutionary dynamics of human influenza B virus

.

J Mol Evol

2008

;

66

:

655

–

63

.

27

Dijkstra

F

,

Donker

GA

,

Wilbrink

B

 et al.

Long time trends in influenza-similar disease and associated determinants in The Netherlands

.

Epidemiol Infect

2009

;

137

:

473

–

9

.

28

Baine

WB

,

Luby

JP

,

Martin

SM.

Severe illness with influenza B

.

Am J Med

1980

;

68

:

181

–

9

.

29

Osterhaus

AD

,

Rimmelzwaan

GF

,

Martina

BE

 et al.

Influenza B virus in seals

.

Science

2000

;

288

:

1051

–

iii

.

30

Ran

Z

,

Shen

H

,

Lang

Y

 et al.

Domestic pigs are susceptible to infection with influenza B viruses

.

J Virol

2015

;

89

:

4818

–

26

.

31

Kawano

J

,

Onta

T

,

Kida

H

,

Yanagawa

R.

Distribution of antibodies in animals against influenza B and C viruses

.

Jpn J Vet Res

1978

;

26

:

74

–

80

.

32

Chang

CP

,

New

AE

,

Taylor

JF

,

Chiang

HS.

Influenza virus isolations from dogs during a homo epidemic in Taiwan

.

Int J Zoonoses

1976

;

3

:

61

–

iv

.

33

Burnham

AJ

,

Baranovich

T

,

Govorkova

EA.

Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance

.

Antiviral Res

2013

;

100

:

520

–

34

.

34

Harper

SA

,

Bradley

JS

,

Englund

JA

 et al.

Seasonal influenza in adults and children–diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical do guidelines of the Infectious Diseases Society of America

.

Clin Infect Dis

2009

;

48

:

1003

–

32

.

35

Kawai

Due north

,

Ikematsu

H

,

Iwaki

N

 et al.

A comparing of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B

.

J Infect

2008

;

56

:

51

–

7

.

36

Bastien

N

,

Gubbay

JB

,

Richardson

D

 et al.

Detection of an influenza B virus strain with reduced susceptibility to neuraminidase inhibitor drugs

.

J Clin Microbiol

2011

;

49

:

4020

–

1

.

37

Belshe

RB.

The need for quadrivalent vaccine against seasonal influenza

.

Vaccine

2010

;

28

:

D45

–

53

.

38

Kauppila

J

,

Ronkko

Eastward

,

Juvonen

R

 et al.

Flu C virus infection in military recruits–symptoms and clinical manifestation

.

J Med Virol

2014

;

86

:

879

–

85

.

39

Roy Mukherjee

T

,

Mukherjee

A

,

Mullick

S

,

Chawla-Sarkar

M.

Full genome assay and label of flu C virus identified in Eastern India

.

Infect Genet Evol

2013

;

16

:

419

–

25

.

twoscore

Smith

DB

,

Gaunt

ER

,

Digard

P

 et al.

Detection of influenza C virus merely non flu D virus in Scottish respiratory samples

.

J Clin Virol

2016

;

74

:

50

–

3

.

41

Ting

PJ

,

Seah

SG

,

Lim

EA

 et al.

Genetic characterisation of influenza C viruses detected in Singapore in 2006

.

Influenza Other Respir Viruses

2016

;

10

:

27

–

33

.

42

Jelley

L

,

Levy

A

,

Deng

YM

 et al.

Influenza C infections in Western Commonwealth of australia and Victoria from 2008 to 2014

.

Influenza Other Respir Viruses

2016

;

10

:

455

–

61

.

43

Guo

YJ

,

Jin

FG

,

Wang

P

 et al.

Isolation of flu C virus from pigs and experimental infection of pigs with influenza C virus

.

J Gen Virol

1983

;

64

:

177

–

82

.

44

Ohwada

K

,

Kitame

F

,

Sugawara

K

 et al.

Distribution of the antibody to influenza C virus in dogs and pigs in Yamagata Prefecture, Japan

.

Microbiol Immunol

1987

;

31

:

1173

–

lxxx

.

45

Salem

E

,

Cook

EAJ

,

Lbacha

HA

 et al.

Serologic evidence for influenza C and D virus amidst Ruminants and Camelids, Africa, 1991-2015

.

Emerg Infect Dis

2017

;

23

:

1556

–

9

.

47

Hause

BM

,

Ducatez

Thousand

,

Collin

EA

 et al.

Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to homo influenza C viruses

.

PLoS Pathog

2013

;

ix

:

e1003176

.

48

Ferguson

50

,

Olivier

AK

,

Genova

S

 et al.

Pathogenesis of Influenza D Virus in Cattle

.

J Virol

2016

;

xc

:

5636

–

42

.

49

White

SK

,

Ma

W

,

McDaniel

CJ

 et al.

Serologic evidence of exposure to influenza D virus amidst persons with occupational contact with cattle

.

J Clin Virol

2016

;

81

:

31

–

three

.

50

Ferguson

L

,

Eckard

L

,

Epperson

WB

 et al.

Influenza D virus infection in Mississippi beefiness cattle

.

Virology

2015

;

486

:

28

–

34

.

51

Foni

East

,

Chiapponi

C

,

Baioni

50

 et al.

Flu D in Italia: towards a meliorate agreement of an emerging viral infection in swine

.

Sci Rep

2017

;

7

:

11660

.

52

Wang

X

,

Anderson

BD

,

Pulscher

LA

 et al.

Epidemiological study of people living in rural North Carolina for novel respiratory viruses

.

Zoonoses Public Wellness

2018

;

65

:

E265

–

9

.

53

Nguyen

TT

,

Poh

MK

,

Low

J

 et al.

Bioaerosol sampling in clinical settings: a promising, noninvasive approach for detecting respiratory viruses

.

Open Forum Infect Dis

2017

;

4

:

ofw259

.

54

Anderson

BD

,

Lednicky

JA

,

Torremorell

M

,

Greyness

GC.

The utilise of bioaerosol sampling for airborne virus surveillance in Swine production facilities: a mini review

.

Front Vet Sci

2017

;

iv

:

121

.

55

Anderson

BD

,

Ma

M

,

Xia

Y

 et al.

Bioaerosol sampling in modernistic agriculture: a novel approach for emerging pathogen surveillance?

J Infect Dis

2016

;

214

:

537

–

45

.

56

Wu

Y

,

Shi

W

,

Lin

J

 et al.

Aerosolized avian influenza A (H5N6) virus isolated from a alive poultry market, Prc

.

J Infect

2017

;

74

:

89

–

91

© The Author(due south) 2018. Published by Oxford Academy Printing on behalf of the Foundation for Evolution, Medicine, and Public Health.

This is an Open Access commodity distributed nether the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in whatsoever medium, provided the original work is properly cited.

© The Author(due south) 2018. Published by Oxford University Printing on behalf of the Foundation for Evolution, Medicine, and Public Health.